Video

VIDEO: iDose yields sustained IOP reduction, few adverse events

CHICAGO – At the American Academy of Ophthalmology meeting, John P. Berdahl, MD, discusses results from the phase 2 clinical trial of iDose (Glaukos), a microinvasive titanium implant that elutes travoprost over time to reduce intraocular pressure.

CHICAGO – At the American Academy of Ophthalmology meeting, John P. Berdahl, MD, discusses results from the phase 2 clinical trial of iDose (Glaukos), a microinvasive titanium implant that elutes travoprost over time to reduce intraocular pressure.

    See more from American Academy of Ophthalmology Meeting